This network meta-analysis suggests osimertinib plus pemetrexed-based chemotherapy as the only regimen demonstrating PFS benefits in the whole cohort and almost all the subgroup analyses, making it the optimal treatment for patients with advanced EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.